Icon plc Stock
€159.60
Your prediction
Icon plc Stock
Pros and Cons of Icon plc in the next few years
Pros
Cons
Performance of Icon plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Icon plc | -2.860% | 0.789% | 12.434% | -21.726% | -22.336% | -21.765% | - |
| Alkermes plc | 0.810% | -0.787% | -3.817% | -14.286% | -10.000% | 2.669% | 61.538% |
| Ironwood Pharmaceuticals | 0.640% | -5.455% | 95.000% | -6.587% | -25.714% | -73.099% | -68.163% |
| Novocure Ltd | -2.220% | -8.174% | -3.254% | -63.646% | -65.282% | -86.701% | -91.689% |
Comments
News
3 Healthcare Pathbreakers With Long-Term Tailwinds
In the world of healthcare stocks, a major innovation, new medical device, or successful drug treatment can cement a firm's position as a leader. Unfortunately, many firms chase after these goals
LVM Capital Management Dumps 16,000 ICON Public Shares Worth $2.6 million
According to an SEC filing dated July 2, 2025, LVM Capital Management reduced its position in ICON Public Limited (NASDAQ:ICLR) by selling 16,096 shares. The transaction was valued at $2.58 million
ICON and Its Employees Recognised as Clinical Research Industry Leaders, and for Innovation and Progress in Sustainability
ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2025 with a number of business awards, recognising the



